Teva Pharmaceutical Industries Limited

NYSE:TEVA Stock Report

Market Cap: US$25.1b

Teva Pharmaceutical Industries Future Growth

Future criteria checks 4/6

Teva Pharmaceutical Industries is forecast to grow earnings and revenue by 65.5% and 2.7% per annum respectively. EPS is expected to grow by 62.9% per annum. Return on equity is forecast to be 31.6% in 3 years.

Key information

65.5%

Earnings growth rate

62.9%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate2.7%
Future return on equity31.6%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Teva: Becoming Increasingly Solid, But No Longer Undervalued

Dec 04

Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Nov 17
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 23

Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Oct 21
Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?

Cheap Teva Stock Should Reward Patient Investors

Sep 09

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 02
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Jul 12
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 14
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)

May 09

Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Mar 26
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Mar 25

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Feb 26

A Review Of Teva's Prospects

Feb 15

Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Jan 07
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry

Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)

Dec 08

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

Jun 15

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Feb 15

Can Teva Pharmaceutical's Q4 results bring positive surprise?

Feb 07

Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment

Jan 19

Tamiflu supplies released from national stockpile as nationwide shortage persists

Jan 12

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

Dec 28

Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex

Dec 16

Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit

Nov 10

Earnings and Revenue Growth Forecasts

NYSE:TEVA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202617,5269723,4351,1728
12/31/202517,0976123,0021,6519
12/31/202416,408-6442,4242949
9/30/202416,772-9591,3681,856N/A
6/30/202416,290-4536791,168N/A
3/31/202416,004-4788781,389N/A
12/31/202315,846-5598421,368N/A
9/30/202315,273-2,3366081,157N/A
6/30/202315,017-2,3501,1731,695N/A
3/31/202314,925-1,7119641,494N/A
12/31/202214,925-2,4461,0421,590N/A
9/30/202215,141-1,2915141,073N/A
6/30/202215,433-1,0544761,059N/A
3/31/202215,557-6155851,154N/A
12/31/202115,878417236798N/A
9/30/202116,23172688673N/A
6/30/202116,324-3,915-131451N/A
3/31/202116,284-3,982-94506N/A
12/31/202016,659-3,9906381,216N/A
9/30/202016,673-4,0319021,423N/A
6/30/202016,78848941,441N/A
3/31/202017,095-825413941N/A
12/31/201916,887-999223748N/A
9/30/201916,396-4,048-42577N/A
6/30/201916,831-4,00784673N/A
3/31/201917,355-3,5594491,062N/A
12/31/201818,271-2,3991,7952,446N/A
9/30/201819,693-11,0592,2332,938N/A
6/30/201820,781-10,256N/A3,312N/A
3/31/201821,800-16,050N/A3,585N/A
12/31/201721,853-16,525N/A2,225N/A
9/30/201723,479-5,963N/A2,791N/A
6/30/201723,425-6,145N/A3,457N/A
3/31/201722,74378N/A3,985N/A
12/31/201621,90368N/A3,890N/A
9/30/201620,2921,591N/A5,415N/A
6/30/201619,5521,346N/A5,047N/A
3/31/201619,4801,697N/A5,564N/A
12/31/201519,6521,573N/A5,542N/A
9/30/201519,9391,775N/A5,679N/A
6/30/201520,1742,548N/A6,010N/A
3/31/201520,2532,757N/A5,583N/A
12/31/201420,2723,055N/A5,127N/A
9/30/201420,5342,748N/A4,191N/A
6/30/201420,5352,583N/A3,211N/A
3/31/201420,4141,383N/A3,033N/A
12/31/201320,3141,269N/A3,237N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TEVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: TEVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TEVA is expected to become profitable in the next 3 years.

Revenue vs Market: TEVA's revenue (2.7% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: TEVA's revenue (2.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TEVA's Return on Equity is forecast to be high in 3 years time (31.6%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:10
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Teva Pharmaceutical Industries Limited is covered by 60 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Richard SilverBarclays
Balaji PrasadBarclays